Cognition Therapeutics (CGTX): Price and Financial Metrics
CGTX Price/Volume Stats
| Current price | $1.93 | 52-week high | $3.49 |
| Prev. close | $1.98 | 52-week low | $0.90 |
| Day low | $1.90 | Volume | 63,396 |
| Day high | $2.00 | Avg. volume | 187,369 |
| 50-day MA | $1.93 | Dividend yield | N/A |
| 200-day MA | $1.68 | Market Cap | 77.28M |
CGTX Stock Price Chart Interactive Chart >
Cognition Therapeutics (CGTX) Company Bio
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest CGTX News From Around the Web
Below are the latest news stories about COGNITION THERAPEUTICS INC that investors may wish to consider to help them evaluate CGTX as an investment opportunity.
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensPURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease.” This episode will feature a review and interactive discussion of the results from Cognition’s Phase 2 SEQUEL study, which were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. During the ep |
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases. The effect of two chemically distinct σ-2 receptor modulators in a mouse model of Alzheimer’s disease on gene and protein expression are presented. Data shed light on the molecular mechanisms |
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease- Top-line results expected mid 2024 -- Strong physician interest drove SHINE study completion - PURCHASE, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the last participant was randomized in the Phase 2 SHINE study (NCT03507790) of CT1812, the company’s lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina. A total of 153 adults with mild-to-moderate (MMSE 18-26 |
Cognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial ResultsCompany's R&D expenses rise while G&A expenses decrease, cash and cash equivalents stand at $33.0 million |
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatePhase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early stage Alzheimer’s disease START trial; will permit approved monoclonal antibody (lecanemab) as combination therapy Complete data from CT1812 SEQUEL EEG study and Phase 2 study design of START trial presented at CTAD 2023 Initiated dosing in MAGNIFY trial for geographic atrophy secondary to dry age-macular degeneration (dry AMD) PURCHASE, N.Y., Nov. |
CGTX Price Returns
| 1-mo | -2.03% |
| 3-mo | -15.72% |
| 6-mo | 82.08% |
| 1-year | 15.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 4.32% |
| 2023 | -11.90% |
| 2022 | -66.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...